BIOHAVEN LTD
BHVNNYSETrading Snapshot
- Day Range
- $14.96 – $15.87
- 52-Week Range
- $7.48 – $18.57
- Volume (shares)
- 3,149,206
- Avg Volume (shares)
- —
- Shares Outstanding
- 151.0M
- Next Earnings
- 2026-11-17
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-4.64
- Dividend Yield
- —
- Dilution (1yr)
- +18.9%
BIOHAVEN LTD
BHVN
StockOtter · stockotter.spaceAbout BIOHAVEN LTD
Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy
One year after Biohaven's first TRAP degrader, BHV-1400, was highlighted in the Kidney Week opening plenary, Biohaven's second TRAP degrader for kidney disease expands its Yale-licensed platform into a growing nephrology
Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again
The Food and Drug Administration agrees to review a New Drug Application for Vyglxia, Biohaven's experimental spinocerebellar ataxia treatment.
Biohaven Rebounds With FDA Review Date for Rare Disease Drug
Biohaven Ltd. (NYSE:BHVN) stock is surging on Thursday with a session volume of 10.293 million versus an average volume of 2.585 million after an update on the spinocerebellar ataxia (SCA) program.
Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement
Biohaven Ltd. (NYSE:BHVN) entered into a licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd.
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phas
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORT